{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:54:48Z","timestamp":1787698488683,"version":"build-2784847793"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1053\/j.semnuclmed.2023.06.003","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T09:48:54Z","timestamp":1687600134000},"page":"69-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["PSMA PET\/CT for Response Assessment of 177Lu-PSMA Therapy"],"prefix":"10.1053","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5622-9849","authenticated-orcid":false,"given":"Philipp E.","family":"Hartrampf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian E.","family":"Serfling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Michalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3372-6046","authenticated-orcid":false,"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0001","first-page":"13n","article-title":"FDA approves pluvicto\/locametz for metastatic castration-resistant prostate cancer","volume":"63","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0002","series-title":"Novartis receives European Commission approval for Pluvicto\u00ae as the first targeted radioligand therapy for treatment of progressive PSMA\u2013positive metastatic castration-resistant prostate cancer","year":"2022"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0003","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0004","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5489\/cuaj.1146","article-title":"PSA-based treatment response criteria in castration-resistant prostate cancer: Promises and limitations","volume":"3","author":"Emmenegger","year":"2009","journal-title":"Can Urol Assoc J"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0005","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0006","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.2967\/jnumed.117.193581","article-title":"Initial experience with volumetric (68)Ga-PSMA I&T PET\/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer","volume":"58","author":"Schmuck","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0007","doi-asserted-by":"crossref","first-page":"122s","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0008","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s00259-017-3887-x","article-title":"Preliminary results on response assessment using (68)Ga-HBED-CC-PSMA PET\/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy","volume":"45","author":"Seitz","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0009","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00259-018-4236-4","article-title":"Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer","volume":"46","author":"Grubm\u00fcller","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0010","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1007\/s00259-021-05594-8","article-title":"Early molecular imaging response assessment based on determination of total viable tumor burden in [(68)Ga]Ga-PSMA-11 PET\/CT independently predicts overall survival in [(177)Lu]Lu-PSMA-617 radioligand therapy","volume":"49","author":"Rosar","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0011","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s00259-018-4042-z","article-title":"(68)Ga-PSMA-11 PET\/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer","volume":"45","author":"Schmidkonz","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0012","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2967\/jnumed.118.224055","article-title":"qPSMA: semiautomatic software for whole-body tumor burden assessment in prostate cancer using (68)Ga-PSMA11 PET\/CT","volume":"60","author":"Gafita","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0013","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3390\/jcm9051390","article-title":"Metabolic tumour volume from PSMA PET\/CT scans of prostate cancer patients during chemotherapy-do different software solutions deliver comparable results?","volume":"9","author":"Hartrampf","year":"2020","journal-title":"J Clin Med"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0014","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2967\/jnumed.122.264489","article-title":"Prognostic value of tumor volume assessment on PSMA PET after (177)Lu-PSMA radioligand therapy evaluated by PSMA PET\/CT consensus statement and RECIP 1.0","volume":"64","author":"Kind","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0015","doi-asserted-by":"crossref","first-page":"678","DOI":"10.2967\/jnumed.119.233817","article-title":"Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET\/CT imaging: The PSMA PET progression criteria","volume":"61","author":"Fanti","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0016","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1111\/bju.12589","article-title":"Radiographic progression by prostate cancer working group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer","volume":"114","author":"Sonpavde","year":"2014","journal-title":"BJU Int"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0017","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.3390\/cancers14184470","article-title":"Bone scintigraphy versus PSMA-targeted PET\/CT or PET\/MRI in prostate cancer: Lessons learned from recent systematic reviews and meta-analyses","volume":"14","author":"Dondi","year":"2022","journal-title":"Cancers"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0018","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.2967\/jnumed.120.260836","article-title":"Assessing response to [(177)Lu]PSMA radioligand therapy using modified PSMA PET progression criteria","volume":"62","author":"Michalski","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0019","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: The EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0020","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","article-title":"Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer","volume":"48","author":"Fanti","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0021","first-page":"1651","article-title":"Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): An international multicenter study","volume":"63","author":"Gafita","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0022","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/biology11050660","article-title":"Reduced segmentation of lesions is comparable to whole-body segmentation for response assessment by PSMA PET\/CT: Initial experience with the keyhole approach","volume":"11","author":"Hartrampf","year":"2022","journal-title":"Biology"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0023","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","article-title":"Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: Comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria","volume":"49","author":"Gafita","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0024","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: The kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0025","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13550-022-00948-1","article-title":"Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET","volume":"12","author":"Leung","year":"2022","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0026","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/diagnostics11020186","article-title":"Estimating the potential of radiomics features and radiomics signature from pretherapeutic PSMA-PET-CT scans and clinical data for prediction of overall survival when treated with (177)Lu-PSMA","volume":"11","author":"Moazemi","year":"2021","journal-title":"Diagnostics"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0027","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/cancers13153849","article-title":"Evaluation of (68)Ga-PSMA-11 PET-MRI in patients with advanced prostate cancer receiving (177)Lu-PSMA-617 therapy: A radiomics analysis","volume":"13","author":"Roll","year":"2021","journal-title":"Cancers"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0028","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7056983","article-title":"High SUVs have more robust repeatability in patients with metastatic prostate cancer: Results from a prospective test-retest cohort imaged with (18)F-DCFPyL","author":"Werner","year":"2022","journal-title":"Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0029","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/pros.24483","article-title":"Lack of repeatability of radiomic features derived from PET scans: Results from a (18) F-DCFPyL test-retest cohort","volume":"83","author":"Werner","year":"2023","journal-title":"Prostate"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0030","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after (177)Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: An international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0031","doi-asserted-by":"crossref","first-page":"103108","DOI":"10.18632\/oncotarget.21600","article-title":"Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy","volume":"8","author":"Ahmadzadehfar","year":"2017","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0032","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1007\/s00259-022-05853-2","article-title":"Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [(177)Lu]Lu-PSMA I&T during long-term follow-up","volume":"49","author":"Hartrampf","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0033","first-page":"P52","article-title":"Unter PSMA-gerichteter radioligandentherapie ist ein h\u00f6herer body-mass-index mit einem verbesserten gesamt\u00fcberleben verbunden","volume":"62","author":"Hartrampf","year":"2023","journal-title":"Nuklearmedizin"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0034","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/pros.24088","article-title":"CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naive oligometastatic prostate cancer","volume":"81","author":"Sheikhbahaei","year":"2021","journal-title":"Prostate"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0035","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2967\/jnumed.117.195255","article-title":"Proposal for a structured reporting system for prostate-specific membrane antigen-targeted PET imaging: PSMA-RADS version 1.0","volume":"59","author":"Rowe","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0036","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.06.003_bib0037","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate cancer molecular imaging standardized evaluation (PROMISE): Proposed miTNM classification for the interpretation of PSMA-Ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J Nucl Med"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299823000508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299823000508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:43:31Z","timestamp":1757544211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299823000508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0001299823000508"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.06.003","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSMA PET\/CT for Response Assessment of 177Lu-PSMA Therapy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}